Shots:

• The P-II/III RELATIVITY-047 (CA224-047) study involves assessing the FD combination of relatlimab (160 mg) + Opdivo (480mg) vs Opdivo (480mg- IV- q4w) alone in 714 patients in a ratio (1:1) with previously untreated metastatic or unresectable melanoma
• The study met its 1EPs of the PFS while the follow-up for 2EPs of OS and ORR is ongoing. The combination was well-tolerated
• Relatlimab is a fully human LAG3-specific Ab- currently being evaluated in clinical trials in combination with other agents in a variety of tumor types

 ­ Ref: BusinessWire | Image: BMS